FDA delays approval of Immunomedics' ADC for triple-negative breast cancer

Immunomedics Inc. (NASDAQ:IMMU) said FDA issued a complete response letter for its BLA for sacituzumab govitecan (IMMU-132) to treat

Read the full 191 word article

User Sign In